Acute Myelomonocytic Leukemia
Associated Genetic Biomarkers
NCI Definition: An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors. (WHO, 2001) 
Acute myelomonocytic leukemias most frequently harbor alterations in DNMT3A, NPM1, FLT3, TET2, and NRAS .
DNMT3A Mutation, NPM1fs, FLT3 Mutation, TET2 Mutation, and FLT3 Exon 14 Mutation are the most common alterations in acute myelomonocytic leukemia .
There is 1 clinical trial for acute myelomonocytic leukemia, of which 1 is open and 0 are completed or closed. Of the trial that contains acute myelomonocytic leukemia as an inclusion criterion, 1 is phase 1 (1 open).
BCR-ABL1, PML-RARA, and t(15;17)(q22;q12) are the most frequent gene inclusion criteria for acute myelomonocytic leukemia clinical trials .
Io-202 is the most common intervention in acute myelomonocytic leukemia clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.